Candidaemia in the non-neutropenic patient: A critique of the guidelines

International Journal of Antimicrobial Agents

Volumn 42, Issue 4, 2013, Pages 294-300

  Deshpande, A ^a   Gaur, S ^b   Bal, A M ^c  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b ROYAL GWENT HOSPITAL   (United Kingdom)

^c CROSSHOUSE HOSPITAL   (United Kingdom)

Author keywords

Candidaemia; Central vascular catheter; Dose dependent susceptibility; Echocardiography; Guidelines; Step down therapy

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; PYRROLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; BLOOD CULTURE; CANDIDEMIA; CANDIDIASIS; CATHETER REMOVAL; CENTRAL VENOUS CATHETER; DRUG CHOICE; DRUG EFFICACY; ECHOCARDIOGRAPHY; EYE EXAMINATION; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; NONHUMAN; PARENTERAL NUTRITION; PHARMACOLOGICAL PROCEDURES; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; TREATMENT INDICATION;

CANDIDAEMIA; CENTRAL VASCULAR CATHETER; DOSE-DEPENDENT SUSCEPTIBILITY; ECHOCARDIOGRAPHY; GUIDELINES; STEP-DOWN THERAPY;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; GUIDELINES AS TOPIC; HUMANS;

EID: 84884701010     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.06.005     Document Type: Review

References (85)

1. J. Morgan, M.I. Meltzer, B.D. Plikaytis, A.N. Sofair, S. Huie-White, and S. Wilcox Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance Infect Control Hosp Epidemiol 26 2005 540 547
2. C.C. Kibbler, S. Seaton, R.A. Barnes, W.R. Gransden, R.E. Holliman, and E.M. Johnson Management and outcome of bloodstream infections due to Candida species in England and Wales J Hosp Infect 54 2003 18 24
3. M.C. Arendrup, S. Sulim, A. Holm, L. Nielsen, S.D. Nielsen, and J.D. Knudsen Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia J Clin Microbiol 49 2011 3300 3308
4. C. Chalmers, S. Gaur, J. Chew, T. Wright, A. Kumar, and S. Mathur Epidemiology and management of candidaemia - a retrospective, multicentre study in five hospitals in the UK Mycoses 54 2011 e795 e800
5. O. Gudlaugsson, S. Gillespie, K. Lee, J. Vande Berg, J. Hu, and S. Messer Attributable mortality of nosocomial candidemia, revisited Clin Infect Dis 37 2003 1172 1177
6. H.M. Blumberg, W.R. Jarvis, J.M. Soucie, J.E. Edwards, J.E. Patterson, and M.A. Pfaller Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey Clin Infect Dis 33 2001 177 186
7. B. Almirante, D. Rodríguez, B.J. Park, M. Cuenca-Estrella, A.M. Planes, and M. Almela Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003 J Clin Microbiol 43 2005 1829 1835
8. A.S. Michalopoulos, S. Geroulanos, and S.D. Mentzelopoulos Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients Chest 124 2003 2244 2255
9. R.P. Wenzel, and C. Gennings Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies Clin Infect Dis 41 Suppl. 2005 S389 S393
10. R.P. Wenzel Nosocomial candidemia: risk factors and attributable mortality Clin Infect Dis 20 1995 1531 1534
11. M. Weinberger, L. Leibovici, S. Perez, Z. Samra, I. Ostfeld, and I. Levi Characteristics of candidaemia with Candida-albicans compared with non-albicans Candida species and predictors of mortality J Hosp Infect 61 2005 146 154
12. A.M. Rentz, M.T. Halpern, and R. Bowden The impact of candidemia on length of hospital stay, outcome, and overall cost of illness Clin Infect Dis 27 1998 781 788
13. L.G. Miller, R.A. Hajjeh, and J.E. Edwards Estimating the cost of nosocomial candidemia in the United States Clin Infect Dis 32 2001 1110
14. J.J. Gagne, and N.I. Goldfarb Candidemia in the in-patient setting: treatment options and economics Expert Opin Pharmacother 8 2007 1643 1650
15. R.E. Lewis Overview of the changing epidemiology of candidemia Curr Med Res Opin 25 2009 1732 1740
16. P.G. Pappas, C.A. Kauffman, D. Andes, D.K. Benjamin, T.F. Calandra Jr., and J.E. Edwards Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 42 2009 503 535
17. E.J. Bow, G. Evans, J. Fuller, M. Laverdiere, C. Rotstein, and R. Rennie Canadian clinical practice guidelines for invasive candidiasis in adults Can J Infect Dis Med Microbiol 21 2010 e122 e150
18. M. Ruhnke, V. Rickerts, O.A. Cornely, D. Buchheidt, A. Glockner, and W. Heinz Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy Mycoses 54 2011 279 310
19. O.A. Cornely, M. Bassetti, T. Calandra, J. Garbino, B.J. Kullberg, and O. Lortholary ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients Clin Microbiol Infect 18 Suppl. 2012 19 37
20. A.L. Colombo, T. Guimaraes, L.F. Camargo, R. Richtmann, F. de Queiroz-Telles, and M.J. Salles Brazilian guidelines for the management of candidiasis - a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical Braz J Infect Dis 17 2013 283 312
21. D.P. Kontoyiannis, G.P. Bodey, and C.S. Mantzoros Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis Mycoses 44 2001 125 135
22. J.H. Rex, J.E. Bennett, A.M. Sugar, P.G. Pappas, C.M. van der Horst, and J.E. Edwards A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute N Engl J Med 331 1994 1325 1330
23. J. Mora-Duarte, R. Betts, C. Rotstein, A.L. Colombo, L. Thompson-Moya, and J. Smietana Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029
24. E.R. Kuse, P. Chetchotisakd, C.A. da Cunha, M. Ruhnke, C. Barrios, and D. Raghunadharao Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Lancet 369 2007 1519 1527
25. B.J. Kullberg, J.D. Sobel, M. Ruhnke, P.G. Pappas, C. Viscoli, and J.H. Rex Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial Lancet 366 2005 1435 1442
26. A.C. Azevedo, F.C. Bizerra, D.A. da Matta, L.P. de Almeida, R. Rosas, and A.L. Colombo In vitro susceptibility of a large collection of Candida strains against fluconazole and voriconazole by using the CLSI disk diffusion assay Mycopathologia 171 2011 411 416
27. V. Krcmery, and A.J. Barnes Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance J Hosp Infect 50 2002 243 260
28. Y. Cohen, P. Karoubi, C. Adrie, R. Gauzit, T. Marsepoil, and D. Zarka Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients Crit Care Med 38 2010 826 830
29. H.K. Choi, S.J. Jeong, H.S. Lee, B.S. Chin, S.H. Choi, and S.H. Han Blood stream infections by Candida glabrata and Candida krusei: a single-center experience Korean J Intern Med 24 2009 263 269
30. M. Segireddy, L.B. Johnson, S.M. Szpunar, and R. Khatib Differences in patient risk factors and source of candidaemia caused by Candida albicans and Candida glabrata Mycoses 54 2011 e39 e43
31. M.Y. Lin, Y. Carmeli, J. Zumsteg, E.L. Flores, J. Tolentino, and P. Sreeramoju Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study Antimicrob Agents Chemother 49 2005 4555 4560
32. G.G. Tapia, R.R. Razonable, J.E. Eckel-Passow, B.D. Lahr, B. Afessa, and M.T. Keegan A scoring model of factors associated with Candida glabrata candidemia among critically ill patients Mycoses 55 2012 228 236
33. D. Abi-Said, E. Anaissie, O. Uzun, I. Raad, H. Pinzcowski, and S. Vartivarian The epidemiology of hematogenous candidiasis caused by different Candida species Clin Infect Dis 24 1997 1122 1128
34. M.L. Moretti, P. Trabasso, L. Lyra, R. Fagnani, M.R. Resende, and L.G. de Oliveira Cardoso Is the incidence of candidemia caused by Candida glabrata increasing in Brazil? Five-year surveillance of Candida bloodstream infection in a university reference hospital in southeast Brazil Med Mycol 51 2013 225 230
35. M. Tumbarello, M. Sanguinetti, E.M. Trecarichi, M. La Sorda, M. Rossi, and E. de Carolis Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome J Antimicrob Chemother 62 2008 1379 1385
36. I. Lee, N.O. Fishman, T.E. Zaoutis, K.H. Morales, M.G. Weiner, and M. Synnestvedt Risk factors for fluconazole-resistant Candida glabrata bloodstream infections Arch Intern Med 169 2009 379 383
37. T. Imtiaz, K.K. Lee, C.A. Munro, D.M. MacCallum, G.S. Shankland, and E.M. Johnson Echinocandin resistance due to simultaneous FKS mutation and increased cell wall chitin in a Candida albicans bloodstream isolate following brief exposure to caspofungin J Med Microbiol 61 2012 1330 1334
38. G.R. Thompson 3rd, N.P. Wiederhold, A.C. Vallor, N.C. Villareal, J.S. Lewis 2nd, and T.F. Patterson Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection Antimicrob Agents Chemother 52 2008 3783 3785
39. M.A. Pfaller, and D.J. Diekema Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012 J Clin Microbiol 50 2012 2846 2856
40. M. Cuenca-Estrella, P.E. Verweij, M.C. Arendrup, S. Arikan-Akdagli, J. Bille, and J.P. Donnelly ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures Clin Microbiol Infect 18 Suppl. 2012 9 18
41. G. Dimopoulos, F. Ntziora, G. Rachiotis, A. Armaganidis, and M.E. Falagas Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome Anesth Analg 106 2008 523 529
42. V.J. Fraser, M. Jones, J. Dunkel, S. Storfer, G. Medoff, and W.C. Dunagan Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality Clin Infect Dis 15 1992 414 421
43. M.A. Pfaller, G.J. Moet, S.A. Messer, R.N. Jones, and M. Castanheira Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009 Antimicrob Agents Chemother 55 2011 561 566
44. L.R. Asmundsdottir, H. Erlendsdottir, and M. Gottfredsson Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011 J Clin Microbiol 51 2013 841 848
45. M.G. Schuster, A. Meibohm, L. Lloyd, and B. Strom Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study J Infect 66 2013 278 284
46. A.Y. Leung, C.S. Chim, P.L. Ho, V.C. Cheng, K.Y. Yuen, and A.K. Lie Candida tropicalis fungaemia in adult patients with haematological malignancies: clinical features and risk factors J Hosp Infect 50 2002 316 319
47. P. Muñoz, M. Giannella, C. Fanciulli, J. Guinea, M. Valerio, and L. Rojas Candida tropicalis fungaemia: incidence, risk factors and mortality in a general hospital Clin Microbiol Infect 17 2011 1538 1545
48. O. Ekenna, R.J. Sherertz, and H. Bingham Natural history of bloodstream infections in a burn patient population: the importance of candidemia Am J Infect Control 21 1993 189 195
49. U. Nawrot, M. Pajaczkowska, M. Fleischer, H. Przondo-Mordarska, A. Samet, and D. Piasecka-Pazik Candidaemia in Polish hospitals - a multicentre survey Mycoses 56 2013 576 581
50. A. Conde-Rosa, R. Amador, D. Pérez-Torres, E. Colón, C. Sánchez-Rivera, and M. Nieves-Plaza Candidemia distribution, associated risk factors, and attributed mortality at a university-based medical center P R Health Sci J 29 2010 26 29
51. S. Schelenz, and W.R. Gransden Candidaemia in a London teaching hospital: analysis of 128 cases over a 7-year period Mycoses 46 2003 390 396
52. A.F. Shorr, D.R. Lazarus, J.H. Sherner, W.L. Jackson, M. Morrel, and V.J. Fraser Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia Crit Care Med 35 2007 1077 1083
53. B.J. Kullberg, P.E. Verweij, M. Akova, M.C. Arendrup, J. Bille, and T. Calandra European expert opinion on the management of invasive candidiasis in adults Clin Microbiol Infect 17 Suppl. 2011 1 12
54. A.C. Reboli, C. Rotstein, P.G. Pappas, S.W. Chapman, D.H. Kett, and D. Kumar Anidulafungin versus fluconazole for invasive candidiasis N Engl J Med 356 2007 2472 2482
55. A.C. Reboli, A.F. Shorr, C. Rotstein, P.G. Pappas, D.H. Kett, and H.T. Schlamm Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome BMC Infect Dis 11 2011 261
56. P. Póvoa, and J. Gonçalves-Pereira Treatment of candidemia in adult patients without neutropenia - an inconvenient truth Crit Care 15 2011 114
57. G.A. Eschenauer, P.L. Carver, S.W. Lin, K.P. Klinker, Y.C. Chen, and B.A. Potoski Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study J Antimicrob Chemother 68 2013 922 926
58. M. Ortega, F. Marco, A. Soriano, M. Almela, J.A. Martínez, and J. López Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008 J Hosp Infect 77 2011 157 161
59. D.J. Marriott, E.G. Playford, S. Chen, M. Slavin, Q. Nguyen, and D. Ellis Determinants of mortality in non-neutropenic ICU patients with candidaemia Crit Care 13 2009 R115
60. M.J. Klevay, E.J. Ernst, J.L. Hollanbaugh, J.G. Miller, M.A. Pfaller, and D.J. Diekema Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection Diagn Microbiol Infect Dis 60 2008 273 277
61. M.H. Nguyen, and C.Y. Yu Voriconazole against fluconazole-susceptible and resistant Candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole J Antimicrob Chemother 42 1998 253 256
62. M.A. Pfaller, D.J. Diekema, M. Mendez, C. Kibbler, P. Erzsebet, and S.C. Chang Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program J Clin Microbiol 44 2006 3551 3556
63. S.A. Messer, R.N. Jones, G.J. Moet, J.T. Kirby, and M. Castanheira Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008) J Clin Microbiol 48 2010 2984 2987
64. M.N. Chitasombat, D.P. Kofteridis, Y. Jiang, J. Tarrand, R.E. Lewis, and D.P. Kontoyiannis Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer J Infect 64 2012 68 75
65. S. Schelenz, R.A. Barnes, C.C. Kibbler, B.L. Jones, and D.W. Denning Standards of care for patients with invasive fungal infections within the United Kingdom: a national audit J Infect 58 2009 145 153
66. J.H. Rex, J.E. Bennett, A.M. Sugar, P.G. Pappas, J. Serody, and J.E. Edwards Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group Clin Infect Dis 21 1995 994 996
67. M.H. Nguyen, J.E. Peacock Jr., D.C. Tanner, A.J. Morris, M.L. Nguyen, and D.R. Snydman Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study Arch Intern Med 155 1995 2429 2435
68. I. Raad, H. Hanna, M. Boktour, E. Girgawy, H. Danawi, and M. Mardani Management of central venous catheters in patients with cancer and candidemia Clin Infect Dis 38 2004 1119 1127
69. C.Y. Liu, L.J. Huang, W.S. Wang, T.L. Chen, C.C. Yen, and M.H. Yang Candidemia in cancer patients: impact of early removal of non-tunneled central venous catheters on outcome J Infect 58 2009 154 160
70. M. Nucci, E. Anaissie, R.F. Betts, B.F. Dupont, C. Wu, and D.N. Buell Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials Clin Infect Dis 51 2010 295 303
71. D.R. Andes, N. Safdar, J.W. Baddley, G. Playford, A.C. Reboli, and J.H. Rex Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials Clin Infect Dis 54 2012 1110 1122
72. L.A. Mermel, M. Allon, E. Bouza, D.E. Craven, P. Flynn, and N.P. O'Grady Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 49 2009 1 45
73. R. Krishna, D. Amuh, C.Y. Lowder, S.M. Gordon, K.A. Adal, and G. Hall Should all patients with candidaemia have an ophthalmic examination to rule out ocular candidiasis? Eye (London) 14 2000 30 34
74. D.W. Parke 2nd, D.B. Jones, and L.O. Gentry Endogenous endophthalmitis among patients with candidemia Ophthalmology 89 1982 789 796
75. R.G. Brooks Prospective study of Candida endophthalmitis in hospitalized patients with candidemia Arch Intern Med 149 1989 2226 2228
76. S.P. Donahue, C.M. Greven, J.J. Zuravleff, A.W. Eller, M.H. Nguyen, and J.E. Peacock Jr. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study Ophthalmology 101 1994 1302 1309
77. S.S. Feman, J.C. Nichols, S.M. Chung, and T.A. Theobald Endophthalmitis in patients with disseminated fungal disease Trans Am Ophthalmol Soc 100 2002 67 70
78. C.P. Shah, J. McKey, M.J. Spirn, and J. Maguire Ocular candidiasis: a review Br J Ophthalmol 92 2008 466 468
79. C.C. Dozier, R.M. Tarantola, K. Jiramongkolchai, and S.P. Donahue Fungal eye disease at a tertiary care center: the utility of routine inpatient consultation Ophthalmology 118 2011 1671 1676
80. M.J. Vinikoor, J. Zoghby, K.L. Cohen, and J.D. Tucker Do all candidemic patients need an ophthalmic examination? Int J Infect Dis 17 2013 e146 e148
81. J.W. Baddley, D.K. Benjamin Jr., M. Patel, J. Miró, E. Athan, and B. Barsic Candida infective endocarditis Eur J Clin Microbiol Infect Dis 27 2008 519 529
82. M. Falcone, N. Barzaghi, G. Carosi, P. Grossi, L. Minoli, and V. Ravasio Candida infective endocarditis: report of 15 cases from a prospective multicenter study Medicine (Baltimore) 88 2009 160 168
83. F.K. Gould, D.W. Denning, T.S. Elliott, J. Foweraker, J.D. Perry, and B.D. Prendergast Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy J Antimicrob Chemother 67 2012 269 289
84. S.K. Mathur, and P. Singh Transoesophageal echocardiography related complications Indian J Anaesth 53 2009 567 574
85. A.L. Colombo, A.L. Ngai, M. Bourque, S.K. Bradshaw, K.M. Strohmaier, and A.F. Taylor Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database Antimicrob Agents Chemother 54 2010 1864 1871